BCT Distributor News
Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Platelets Treated by Mirasol® Are Safe and Effective According to Trial Results

​​

New Trial Results Show Platelets Treated With the Mirasol® Pathogen Reduction Technology (PRT) System Are Safe and Effective

The results of the PREPAReS clinical study published earlier this year in Blood, the official journal of the American Society of Hematology, added to the growing clinical evidence that platelets treated by the Mirasol system are safe and effective.1

 

PREPAReS, or Pathogen Reduction Evaluation & Predictive Analytical Rating Score, was the most comprehensive clinical trial to date and compared Mirasol-treated platelets to conventional platelets in plasma prepared using the buffy coat method. The trial concluded that there was no clinical difference (noninferiority) between the treated and conventional platelets.

 

The trial evaluated patients with thrombocytopenia, a low-platelet-count condition that is frequently caused either by illnesses such as leukemia or as a side effect of medications such as chemotherapy drugs. Ensuring the safety of blood products for this patient population is critical as thrombocytopenic patients may receive multiple transfusions.

 

"The PREPAReS results are very meaningful for all healthcare providers concerned about the ongoing safety of blood as we continue to see new pathogens emerge," says Jean-Louis Kerkhoffs, Senior Researcher, Department of Clinical Transfusion Research at Sanquin and Hematologist, in The HagaZiekenhuis in The Hague.

 

In routine use since 2009, Mirasol is now used in more than 20 countries in Europe, the Middle East, Latin America and throughout the Asia-Pacific region. No serious adverse events have been reported after more than 750,000 Mirasol disposable kits sold and about 190,000 recorded transfusions of Mirasol-treated products.

 

"Terumo BCT is dedicated to advancing blood safety throughout the world. Mirasol is a proactive approach to protecting patients, including those who frequently need transfusions," says Palani Palaniappan, Executive Vice President, Innovation and Development, Terumo BCT. "We continue working toward global adoption of Mirasol."

 

To learn more, download the PREPAReS Clinical Study Brochure and the complete list of Mirasol Clinical Trials.​

 

1van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trial. Blood. 2018;128:223-231. https://doi.org/10.1182/blood-2018-02-831289.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}